| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J1453 | Fosaprepitant | Emend | 150 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | No | 2008 | Jan 1, 2009 | In Use | ||
| NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 0.3 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
| NA | Rucaparib | Rubraca | 300 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
| J9262 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | Jan 1, 2014 | In Use | ||
| J9263 | Oxaliplatin | Eloxatin | 0.5 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 2002 | Jan 1, 2004 | In Use | ||
| J9311 | Rituximab and Hyaluronidase | Rituxan Hycela | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2017 | Jan 1, 2019 | In Use | ||
| NA | Trametinib | Mekinist | 2 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
| Q5112 | Trastuzumab-dttb | Ontruzant | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2021 | Jul 1, 2019 | In Use | ||
| J9045 | Carboplatin | Carboplatin | 50 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 1989 | Jan 1, 1990 | In Use | ||
| J9213 | Interferon Alfa-2a | Roeferon- A | 3 million units | Immunotherapy | Cytokine | Interferon | No | 2002 | Jan 1, 2009 | In Use | ||
| Tovorafenib | Ojemda | 25mg, 100mg | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Yes | 2024 | In Use | ||||
| J9200 | Floxuridine | Floxuridine | 500 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1970 | Jan 1, 1984 | In Use | ||
| J9202 | Goserelin Acetate | Zoladex | 3.6 mg | Hormonal Therapy | GnRH Agonist | No | 1989 | Jan 1, 1997 | In Use | |||
| J9293 | Mitoxantrone | Mitoxantrone | pr 5 mg | Chemotherapy | Antitumor Antibiotic | Anthracenedione | No | 1987 | Jan 1, 1990 | In Use | ||
| NA | Cedazuridine and Decitabine | Inqovi | 100mg, 35mg | Chemotherapy | Antimetabolite | Pyrimidine Analog + CDA Inhibitor | Yes | 2020 | In Use | |||
| NA | Fluorouracil | Carac, Efudex | topical, varies | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1970 | In Use | |||
| NA | Gardasil-9 | Human papillomavirus vaccine | Ancillary Therapy | Protective Agent | HPV Vaccine | No | 2016 | In Use | ||||
| J9201 | Gemcitabine | Gemzar | 200 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1996 | Jan 1, 1998 | In Use | ||
| NA | Pilocarpine Hydrochloride | Pilocarpine | 5mg, 10mg | Ancillary Therapy | Miscellaneous Agent | Cholinergic Agent | Yes | 2020 | In Use | |||
| J9361 | Efbemalenograstim alfa-vuxw | Ryzneuta | 0.5mg | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2023 | Jun 10, 2024 | In Use | ||
| Vimseltinib | Romvimza | 14mg, 20mg, 30mg | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Yes | 2025 | In Use | ||||
| S0108 | Mercaptopurine | Mercaptopurine | 50 mg | Chemotherapy | Antimetabolite | Purine Analog | Yes | 1953 | Apr 1, 2002 | In Use | ||
| J8655 | Netupitant/Palonosetron | Akynzeo | 300mg/0.5 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist, Substance P/Neurokinin 1 | Yes | 2014 | Jan 1, 2016 | In Use | ||
| NA | Ponatinib | Iclusig | 45 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
| BA | Belzutifan | Welireg | 40mg | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Yes | 2021 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home